Literature DB >> 415850

The role of de novo purine synthesis in lymphocyte transformation.

A C Allison, T Hovi, R W Watts, A D Webster.   

Abstract

Genetic defects in purine metabolism are associated with severe immunodeficiency. Adenosine deaminase deficiency impairs the function of both B- and T-lymphocytes whereas in purine nucleoside (inosine) phosphorylase deficiency there is more severe impairment of T-lymphocyte functions than of B-lymphocyte functions. The relative unimportance of the salvage pathway catalysed by hypoxanthine-guanine phosphoribosyltransferase is shown by the normal responses of T-lymphocytes from patients with the Lesch-Nyhan syndrome to antigenic and mitogenic stimulation. A mild deficiency of B-lymphocyte function is found in these patients. Agents inhibiting the de novo pathway of purine synthesis, including azaserine, 6-mercaptopurine and azathioprine in low doses, block the responses of normal human lymphocytes to mitogenic stimulation. These observations emphasize the importance of the de novo pathway of purine synthesis in lymphocyte responses to antigenic and mitogenic stimulation. There is considerable heterogeneity in the amount of labelled uridine incorporated into human and rat lymphocytes. This does not appear to reflect only a difference between T- and B-lymphocytes

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 415850     DOI: 10.1002/9780470720301.ch13

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  24 in total

Review 1.  [Systemic immunosuppressives after penetrating keratoplasty].

Authors:  A Reis; F Birnbaum; T Reinhard
Journal:  Ophthalmologe       Date:  2007-05       Impact factor: 1.059

2.  TRPM7 ion channels are required for sustained phosphoinositide 3-kinase signaling in lymphocytes.

Authors:  Jaya Sahni; Andrew M Scharenberg
Journal:  Cell Metab       Date:  2008-07       Impact factor: 27.287

3.  Purine metabolism in lymphocytes from patients with primary hypogammaglobulinaemia.

Authors:  A D Webster; M North; J Allsop; G L Asherson; R W Watts
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

4.  Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design.

Authors:  T D Colby; K Vanderveen; M D Strickler; G D Markham; B M Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

5.  Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial.

Authors:  A Reis; T Reinhard; A Voiculescu; B Kutkuhn; E Godehardt; H Spelsberg; C Althaus; R Sundmacher
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

Review 6.  The design and development of an immunosuppressive drug, mycophenolate mofetil.

Authors:  A C Allison; E M Eugui
Journal:  Springer Semin Immunopathol       Date:  1993

7.  Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model.

Authors:  A Reis; T Reinhard; R Sundmacher; C Braunstein; E Godehardt
Journal:  Br J Ophthalmol       Date:  1998-06       Impact factor: 4.638

8.  Effects of mycophenolate mofetil on proliferation and mucin-5AC expression in human conjunctival goblet cells in vitro.

Authors:  Hong He; Hui Ding; Aiping Liao; Qiong Liu; Jun Yang; Xingwu Zhong
Journal:  Mol Vis       Date:  2010-10-01       Impact factor: 2.367

9.  Azathioprine and 6-mercaptopurine (6-MP) suppress the human mixed lymphocyte reaction (MLR) by different mechanisms.

Authors:  S A Al-Safi; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

Review 10.  Mizoribine: a new approach in the treatment of renal disease.

Authors:  Yukihiko Kawasaki
Journal:  Clin Dev Immunol       Date:  2009-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.